15 results about "Clostridium difficile (bacteria)" patented technology

The present application belongs to the technical field of bacterial detection, and particularly relates to a Clostridium difficile multi-locus genotyping detection kit and application thereof. The present application aims to provide a new method to directly type a main Clostridium difficile strain sequence type (ST). The technical scheme of the present application is a multiplex fluorescence PCR primer set and probe for Clostridium difficile multi-locus genotyping detection, wherein the primer and probe are shown in Seq ID No. 1-18. The present application discloses a multiplex fluorescence PCR reagent for 7 main ST types of Clostridium difficile based on a fluorescence PCR-dissolution curve method. The reagent can simultaneously detect 7 main ST types of Clostridium difficile in the same PCR reaction system.

The invention discloses a primer group for simultaneously detecting four equine digestive tract bacteria and application thereof, the primer group comprises primer sequences as shown in SEQ ID NO: 1-8, and the four equine digestive tract bacteria are salmonella enteritidis, salmonella typhimurium, clostridium difficile and lawsonia intracellular. Extracting total DNA (deoxyribonucleic acid) of a sample to be detected by using the excrement sample nucleic acid extraction kit; the total DNA is used as a template, and the primer group is used for multiple PCR reaction to obtain an amplification curve. According to the invention, a primer sequence with high sensitivity and specificity is adopted, so that the quality of a detection result is ensured; the detection method is simple to operate, time-saving and labor-saving; the detection flux is high, and the reagent consumable cost is low.

A method of manufacturing ostrich antibodies may include immunizing mature female ostriches with a mixture solution comprising Clostridium difficile toxin A and toxin B, obtaining eggs from the immunized ostriches, and purifying egg yolk antibodies from the eggs.

Bacterial infections evading the current antibiotic arsenal warrant new treatment options. The mainstay treatment for Clostridium difficile infections involves administration of the broad-spectrum antibiotic vancomycin, which also depletes the gut microbiome and its natural defenses. This leads to recurrent C. difficile infections in 20-30% of patients. Alternative treatment options are limited, triggering a perpetual cycle of relapse and recovery that may eventually lead to death. Keratinicyclin B represents a glycopeptide antibiotic chemotype with a mechanism of action that is selective for Clostridia. When combined, vancomycin (or other glycopeptide antibiotic) and keratinicyclin B interact synergistically to inhibit the growth of C. difficile at concentrations far lower than their respective minimal inhibitory concentrations. Such a combination therapy could allow for targeted colonization clearance at low antibiotic doses, thereby minimizing toxicity and reducing the likelihood of relapse.

The present invention relates to a bacterial strain of the species Fecalibacterium prausnitzii, which has been preserved in CNCM with a preservation number CNCM I-4573, and / or a culture supernatant thereof, for use in the treatment and / or prevention of a Clostridium difficile infection in an individual. The present invention also relates to a method for producing the bacterial strain of the species Fecalibacterium prausnitzii, and to a method for producing the bacterial strain of the species Fecalibacterium prausnitzii, which has been preserved in CNCM with a preservation number CNCM I-4573.

A bio-sensor device for the electrochemical detection of a bacterial pathogen, the device including a sample chamber and an electronic data module. The sample chamber includes passive sensing probes to detect pathogenic antigens in a sample containing the bacterial pathogen. The probes detect a reaction voltage corresponding to an antigen-antibody reaction occurring when the pathogenic antigens come into contact with an antibody specific for pathogenic antigens present in in the contents of the sample chamber and contacted by the electrical probes. The electronic data module detects and processes electrical signals detected by the conductive electrical probes corresponding to an amount of the antigen present in the sample, wherein the reaction voltage is detected at the time of the reaction.

The invention discloses a bacterial strain for preventing and treating diarrhea caused by clostridium difficile infection and application of the bacterial strain. The bacterial strain is saccharomyces boulardii HS5 and is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC NO.31317. The invention further discloses a preparation method of the bacterial strain for preventing and treating diarrhea caused by clostridium difficile infection and application of the bacterial strain for preventing and treating diarrhea caused by clostridium difficile infection. The preservation time is October 11, 2021; the bacterial strain for preventing and treating diarrhea caused by clostridium difficile infection is obtained through screening, the bacterial strain can remarkably inhibit growth of clostridium difficile, has excellent antibacterial performance on clostridium difficile, can further prevent and improve diarrhea symptoms caused by clostridium difficile infection, and is quick in effect and remarkable in effect.

The inventors of the present disclosure have undergone in-depth studies and found that an antibody that binds to and inhibits the proliferation of intestinal bacteria, particularly clostridium difficile cells and other intestinal bacteria cells. The present disclosure exerts the effect of providing antibodies and antigen-binding fragments thereof that bind to enteral bacteria, in particular, clostridium difficile and other enteral bacteria, and uses thereof.

The present invention provides an allocholic acid derivative having antibacterial activity and a pharmaceutical composition thereof, belonging to the field of medical technology. The allocholic acid derivative is a compound represented by formula (I), or a stereoisomer thereof, or a salt thereof, or a solvate thereof, or a prodrug thereof, or a metabolite thereof. This type of compound can effectively inhibit the growth of Clostridium difficile bacteria, has significant antibacterial activity, and has very good application prospects in the preparation of drugs for preventing and / or treating Clostridium difficile infectious diseases, recurrence of Clostridium difficile infectious diseases, or complications of Clostridium difficile infectious diseases.

The present invention relates to a composition comprising a monoclonal antibody binding to Clostridium difficile (C. difficile) for inhibiting a growth of Clostridium difficile (C. difficile), and a use thereof. In addition, the present invention discloses the composition for treating an inflammatory bowel disease, and a use thereof.

The invention provides Escherichia coli YC49 and application of the Escherichia coli YC49 in inhibiting clostridium difficile in cooperation with bacteroides, and belongs to the technical field of microorganisms. The invention provides Escherichia coli YC49, and the preservation number of the Escherichia coli YC49 is CGMCC (China General Microbiological Culture Collection Center) No. 34488. The invention also provides an effect of the Escherichia coli YC49 and bacteroides on synergistically inhibiting clostridium difficile, and further provides a compound probiotic composition, an in-vitro antibacterial product and a coprophilous fungus transplantation product. The Escherichia coli YC49 can accelerate the whole process from growth to decline of clostridium difficile, and a culture solution obtained after the Escherichia coli YC49 is combined with common bacteroides or the Escherichia coli YC49 and the common bacteroides are co-cultured can remarkably inhibit growth of early-stage clostridium difficile, so that the Escherichia coli YC49 has application significance in treatment of clostridium difficile infection.

The invention discloses a lactobacillus reuteri and a preparation method and application of a microbial inoculum of the lactobacillus reuteri, the lactobacillus reuteri subsp.reuteri OH114 is preserved in Guangdong Province Microbial Culture Collection Center (GDMCC), the preservation address is No.59 building, No.100 courtyard, Xianlie Middle Road, Guangzhou, the preservation number is GDMCC No.66528, and the preservation time is June 16, 2025. The lactobacillus reuteri newly researched and developed by the invention can effectively inhibit the growth of a plurality of enteropathogenic bacteria such as staphylococcus aureus, escherichia coli, salmonella typhimurium, clostridium difficile, clostridium perfringens, klebsiella pneumoniae, pseudomonas aeruginosa and candida albicans, regulate the balance of intestinal flora, prevent and treat adult diarrhea, and prevent and treat diarrhea. The invention provides a new scheme and way for preventing and treating infectious diarrhea, antibiotic-related diarrhea or irritable bowel syndrome diarrhea.

This document describes compositions, methods, and kits for detecting diarrheal pathogens from patient, food, or environmental samples. One embodiment described herein is primer pairs and probes for a multiplex polymerase chain reaction (PCR)-based assay for detecting gastrointestinal pathogens such as adenovirus, astrovirus, rotavirus, norovirus, zaruzin virus, Campylobacter species, Clostridium difficile, enteroaggregative Escherichia coli (EAEC), enteropathogenic Escherichia coli (EPEC), enterotoxin-producing Escherichia coli (ETEC), Shigella-like toxin-producing Escherichia coli (STEC), Shigella spp. / enteroinvasive Escherichia coli (EIEC), Escherichia coli O157, Listeria monocytogenes, Shigella-like bacteria, Salmonella spp., Yersinia enterocolitica, Vibrio species, Cryptosporidium species, Cyclospora kayanoides, Entamoeba histolytica, Giardia lamblia, or Giardia lamblia. Other embodiments include methods and kits for detecting gastrointestinal pathogens.

The application discloses a lactobacillus rhamnosus A21174 for inhibiting infection of multi-drug resistant strains and clostridium difficile, and application thereof. The lactobacillus rhamnosus A21174 has obvious inhibiting effect on drug-resistant staphylococcus aureus, pseudomonas aeruginosa, drug-resistant escherichia coli, drug-resistant acinetobacter baumannii and a model strain of clostridium difficile. Compared with a commercial strain of lactobacillus rhamnosus, the lactobacillus rhamnosus A21174 has better bacteriostatic effect on clostridium difficile. The lactobacillus rhamnosus A21174 also shows good effect in in-vivo and in-vitro experiments such as resistance to artificial gastric and intestinal fluid, resistance to bile salt, anti-aging, anti-oxidation, improvement of cognition and the like, and therefore, the strain can be used as a probiotic agent to prepare a product for regulating intestinal flora, and has important significance for preventing and / or treating diseases caused by infection of multi-drug resistant bacteria, clostridium difficile and pseudomonas aeruginosa.

The invention relates to the field of microorganisms, and discloses a microbial agent for inhibiting growth of clostridium difficile and enterococcus faecalis and application of the microbial agent. The microbial agent is prepared from bifidobacterium longum, lactobacillus delbrueckii subsp. Bulgaricus, bifidobacterium breve, lactobacillus reuteri, ackermann mucilaginosus and bacteroides ovatus. The six strains in the microbial inoculum cooperate to form a thick and dense symbiotic biological membrane, the thick and dense symbiotic biological membrane is rapidly planted in a symbiotic system of clostridium difficile (CD) and enterococcus faecalis (EF), a physical barrier is constructed, and colonization and diffusion of the clostridium difficile (CD) and the enterococcus faecalis (EF) are spatially inhibited; meanwhile, the content of leucine and ornithine secreted by EF in a system is remarkably reduced through metabolism synergy, cross-breeding of the leucine and the ornithine is blocked, growth is inhibited, CD spore germination can be inhibited by 100%, CD toxin secretion is reduced, the yield of pathogenic symbiotic biological membranes is reduced, CD pathogenicity is weakened in multiple links, all-around intervention on co-infection of CD and EF is achieved, and the application prospect is wide. And an efficient and safe solution is provided for the clinical problem.